| |
| |
|
| Insider
Information: |
Gionco David |
| Relationship: |
Chief Accounting Officer |
| City: |
East Brunswick |
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
35,764 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
35,764 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 688.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Savient Pharmaceuticals Inc |
SVNTQ |
Chief Accounting Officer |
2013-10-15 |
35,764 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Chief Accounting Officer |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SVNTQ |
Savient Pharmaceuticals I... |
Group Vice President, CFO |
• – – |
2010-09-16 |
4 |
A |
$20.27 |
$464,548 |
D/D |
22,918 |
54,073 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
Group VP, CFO |
• – – |
2009-09-14 |
4 |
S |
$15.36 |
$167,224 |
D/D |
(10,887) |
35,895 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
Group Vice President, CFO |
• – – |
2010-09-16 |
4 |
D |
$20.27 |
$164,552 |
D/D |
(8,118) |
45,955 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2018-03-12 |
4 |
S |
$17.20 |
$159,595 |
D/D |
(9,183) |
180,684 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2019-03-11 |
4 |
S |
$11.11 |
$149,896 |
D/D |
(13,492) |
225,468 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
Group VP, CFO |
• – – |
2009-09-15 |
4 |
S |
$15.95 |
$119,625 |
D/D |
(7,500) |
35,895 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2019-02-25 |
4 |
S |
$12.03 |
$103,013 |
D/D |
(8,563) |
240,341 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2020-02-25 |
4 |
S |
$6.43 |
$58,815 |
D/D |
(9,147) |
333,591 |
0 |
% |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2018-01-17 |
4 |
S |
$13.43 |
$57,078 |
D/D |
(4,250) |
162,538 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2020-04-01 |
4 |
S |
$4.79 |
$55,200 |
D/D |
(11,524) |
282,878 |
0 |
% |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2015-01-20 |
4 |
S |
$14.22 |
$47,082 |
D/D |
(3,311) |
26,689 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2020-03-10 |
4 |
S |
$4.92 |
$43,522 |
D/D |
(8,846) |
319,734 |
0 |
% |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2017-01-19 |
4 |
S |
$11.46 |
$41,176 |
D/D |
(3,593) |
103,392 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
Group VP, CFO |
• – – |
2009-09-15 |
4 |
OE |
$4.32 |
$32,400 |
D/D |
7,500 |
43,395 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2019-12-24 |
4 |
S |
$10.97 |
$26,196 |
D/D |
(2,388) |
237,129 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
Group VP & CFO |
• – – |
2010-02-09 |
4 |
AS |
$12.77 |
$26,003 |
D/D |
(2,037) |
32,408 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2020-03-09 |
4 |
S |
$5.08 |
$25,456 |
D/D |
(5,011) |
328,580 |
0 |
% |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2017-02-27 |
4 |
S |
$6.97 |
$24,395 |
D/D |
(3,500) |
99,892 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2018-03-07 |
4 |
S |
$16.56 |
$23,399 |
D/D |
(1,413) |
152,275 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2017-02-28 |
4 |
S |
$7.01 |
$20,932 |
D/D |
(2,986) |
96,906 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
Group VP & CFO |
• – – |
2011-01-24 |
4 |
AS |
$10.00 |
$20,320 |
D/D |
(2,032) |
42,735 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
VP, CFO |
• – – |
2009-12-21 |
4 |
AS |
$12.95 |
$19,561 |
D/D |
(1,511) |
34,445 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
Group VP & CFO |
• – – |
2010-12-20 |
4 |
AS |
$11.87 |
$18,233 |
D/D |
(1,536) |
44,419 |
0 |
- |
|
| SVNTQ |
Savient Pharmaceuticals I... |
Group VP & CFO |
• – – |
2010-02-16 |
4 |
AS |
$13.81 |
$17,300 |
D/D |
(1,253) |
31,155 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Accounting Officer |
• – – |
2019-12-26 |
4 |
S |
$10.75 |
$16,243 |
D/D |
(1,511) |
235,618 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
